Litigation Details for CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)
✉ Email this page to a colleague
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)
| Docket | See Plans and Pricing | Date Filed | 2019-07-12 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 28:1338 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 10,555,939; 6,045,501; 6,281,230; 6,315,720; 6,476,052; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 7,119,106; 7,189,740; 7,393,862; 7,465,800; 7,468,363; 7,855,217; 7,959,566; 7,968,569; 8,188,118; 8,198,262; 8,204,763; 8,315,886; 8,530,498; 8,626,531; 8,648,095; 8,673,939; 8,735,428; 8,828,427; 9,101,621; 9,101,622; 9,993,467 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Biologic Drugs cited in CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.
The biologic drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-07-12 | 1 | Complaint | 6,045,501 A 4/2000 Elsayed et al. …8,673,939 (the “’939 patent”), 8,735,428 (the “’428 patent”), 8,828,427 (the “’427 patent”), and 9,993,467… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…the expiration of United States Patent Nos. 8,198,262 (the “’262 patent”), Case 2:19-cv-15343-ES-MAH Document…9,993,467 (the “’467 patent”), all owned by Celgene (collectively, “the patents-in-suit”). | External link to document |
| 2022-01-27 | 145 | Letter | 10,093,648; 10,093,649; and 10,555,939 and (2) a Final Judgment Regarding U.S. Patent Nos. 8,198,262 and 8,…10,093,649; and 10,555,939. 4. Until expiration of the Patents-in-Suit, DRL, including… others, U.S. Patent Nos. 8,198,262 (the “’262 patent”) and 8,828,427 (the “’427 patent”), and pursuant… the ’262 patent is valid, enforceable, entitled to the patent term adjustments and patent term extensions…262 patent as well as the propriety and enforceability of the patent term adjustments and patent term | External link to document |
| 2022-02-22 | 148 | Order | FINAL JUDGMENT REGARDING U.S. PATENT NOS. 8,198,262 AND 8,828,427, etc. Signed by Judge Esther … 12 July 2019 2:19-cv-15343 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
